<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011253</url>
  </required_header>
  <id_info>
    <org_study_id>QI-MH</org_study_id>
    <nct_id>NCT05011253</nct_id>
  </id_info>
  <brief_title>Electronic Triggers: Microhematuria Trigger</brief_title>
  <official_title>Electronic Trigger for Microhematuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research team will evaluate the effectiveness of an InBasket Results message that prompts&#xD;
      providers to place appropriate follow up orders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research team will evaluate the effectiveness of an InBasket Results message that prompts&#xD;
      providers to place appropriate follow up orders. The message will notify users that a patient&#xD;
      has clinically significant microscopic hematuria and is at high risk for underlying&#xD;
      malignancy and will include the official recommendations (imaging with a CT urogram, urology&#xD;
      evaluation with cystoscopy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation rate</measure>
    <time_frame>180 days of alert</time_frame>
    <description>Urology evaluation with cystoscopy and appropriate imaging</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Hematuria</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <description>The group which will receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria and makes recommendations for follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>The group which will not receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria. (Standard practice)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Trigger Microhematuria Alert</intervention_name>
    <description>To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All NYU outpatients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  35 years of age or older&#xD;
&#xD;
          -  3+ RBC on Urinalysis&#xD;
&#xD;
          -  Urinalysis sent during an outpatient encounter&#xD;
&#xD;
          -  any of the following: 60 years of age or older; RBC &gt; 25; current or prior tobacco&#xD;
             use; Gross Hematuria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 35 years of age&#xD;
&#xD;
          -  Cystoscopy within 1 year prior to Urinalysis&#xD;
&#xD;
          -  Nitrite positive AND Leukocyte Esterase positive&#xD;
&#xD;
          -  Nitrite positive AND &gt;100 WBC&#xD;
&#xD;
          -  Leukocyte Esterase positive AND &gt;100 WBC&#xD;
&#xD;
          -  Know GU cancer diagnosis&#xD;
&#xD;
          -  Urinalysis ordered by urology provider&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saul Blecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jay Stadelman, MPH</last_name>
    <phone>646-501-2697</phone>
    <email>jay.stadelman@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saul Blecker, MD</last_name>
    <email>saul.blecker@nyulangone.org</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

